INCR Intercure

InterCure Reschedules 2022 Full Year Results Conference Call

InterCure Reschedules 2022 Full Year Results Conference Call

NEW YORK, TORONTO, and HERZLIYA, Israel, April 03, 2023 (GLOBE NEWSWIRE) -- . (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the “Company”) announced today that it has rescheduled its previously announced conference call to discuss the company's financial results for the full year ended December 31, 2022.

The call was originally scheduled for April 3 at 4:30 P.M. (Eastren time) but has been rescheduled to April 4, at 4:30 P.M. (Eastren time) due to unforeseen circumstances which caused technical issues.

Participants can access the live webcast and conference call through the following link:

About InterCure (dba Canndoc)

InterCure (dba Canndoc) (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) is the leading, profitable, and fastest growing cannabis company outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its international market leading distribution network, best in class international partnerships and a high-margin vertically integrated "seed-to-sale" model to lead the fastest growing cannabis global market outside of North America.

For more information, visit: .

Contact:

InterCure Ltd.

Amos Cohen, Chief Financial Officer



EN
03/04/2023

Underlying

INCRIntercure

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Intercure

 PRESS RELEASE
Free
INCR INTERCURE

InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Mill...

InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash of NIS 43 Million InterCure reports preliminary estimated revenue of NIS 265 million for 2025 and positive Adjusted EBITDA, marking its twelfth consecutive half-year of positive Adjusted EBITDA. Revenue for 2025 represents an increase of approximately 11% compared to 2024, while revenue for the second half of 2025 is nearly 20% higher than the corresponding period in the prior year. During the second half of 2025, the Company generated its first significant revenues from the German...

February 19, 2026 1 EN
 PRESS RELEASE
Free
INCR INTERCURE

InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Mill...

InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash¹ of NIS 43 Million InterCure reports preliminary estimated revenue of NIS 265 million for 2025 and positive Adjusted EBITDA2, marking its twelfth consecutive half-year of positive Adjusted EBITDA. Revenue for 2025 represents an increase of approximately 11% compared to 2024, while revenue for the second half of 2025 is nearly 20% higher than the corresponding period in the prior year. During the second half of 2025, the Company generated its first significant revenues from the Germ...

February 19, 2026 1 EN
 PRESS RELEASE
Free
INCR INTERCURE

InterCure and Cannasoul Sign Strategic Investment and Collaboration Ag...

InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation Agreements formalize research partnership combining InterCure’s global pharmaceutical platform with Cannasoul’s world-class analytics and scientific innovation Collaboration comes amidst reports that the Trump administration is exploring cannabis rescheduling, expected to create unprecedented opportunities in the U.S. for international operators like InterCure NEW YORK & HERZLIYA, Israel , Nov. 03, 2025 (GLOBE NEWSWIRE) -- InterCure Ltd. (Nasdaq: INCR...

November 3, 2025 1 EN
 PRESS RELEASE
Free
INCR INTERCURE

InterCure Reports First Half 2025 Results with NIS 130 Million in Reve...

InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow The Company reports NIS 130 million in revenue and NIS 12 million in positive operating cash flow, demonstrating resilience and sustained profitability with its eleventh consecutive half of positive Adjusted EBITDA amidst ongoing recovery in Israel InterCure is encouraged by recent regulatory momentum in the U.S. and believes that it is well positioned to capitalize on evolving U.S. cannabis rescheduling, especially following its recent signing of an agreement to acquire ISHI NEW YOR...

October 8, 2025 1 EN
 PRESS RELEASE
Free
INCR INTERCURE

InterCure Reports First Half 2025 Results with NIS 130 Million in Reve...

InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow The Company reports NIS 130 million in revenue and NIS 12 million in positive operating cash flow, demonstrating resilience and sustained profitability with its eleventh consecutive half of positive Adjusted EBITDA amidst ongoing recovery in Israel InterCure is encouraged by recent regulatory momentum in the U.S. and believes that it is well positioned to capitalize on evolving U.S. cannabis rescheduling, especially following its recent signing of an agreement to acquire ISHI NEW YOR...

October 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch